A solid particulate formulation comprising soluble ferric pyrophosphate and a sachet comprising the solid particulate formulation of soluble ferric pyrophosphate for adding to a dialysis solution are provided. Improved methods of administering soluble ferric pyrophosphate comprising the solid particulate formulations and kits comprising the solid particulate formulation and a dialysis concentrate formulation are also disclosed.

A pharmaceutical composition for oral administration and a use of a pharmaceutical composition for preparing oral medication for delivering nitric oxide to the patient's circulatory system or brain are provided. The pharmaceutical composition mainly includes a dinitrosyl iron complex and a pharmaceutically acceptable excipient. The pharmaceutical composition delivers nitric oxide to the patient's circulatory system or brain to stimulate neurogenesis or regulate blood sugar.

A pharmaceutical composition for oral administration and a use of a pharmaceutical composition for preparing oral medication for delivering nitric oxide to the patient's circulatory system or brain are provided. The pharmaceutical composition mainly includes a dinitrosyl iron complex and a pharmaceutically acceptable excipient. The pharmaceutical composition delivers nitric oxide to the patient's circulatory system or brain to stimulate neurogenesis or regulate blood sugar.

An external dermal composition and a method for beautifying skin are provided. The external dermal composition mainly includes a double nitrosyl-iron complex and a pharmaceutically acceptable additive. The external dermal composition delivers nitric oxide to a user's skin to beautify the skin when applied to the user's skin.

Disclosed herein are prenatal dosage forms formulated for different stages of the pregnancy cycle. Also disclosed are methods of administering prenatal dosage forms to a prenatal, pregnant or lactating woman. Further disclosed are kits including prenatal dosage forms.

Disclosed herein are prenatal dosage forms formulated for different stages of the pregnancy cycle. Also disclosed are methods of administering prenatal dosage forms to a prenatal, pregnant or lactating woman. Further disclosed are kits including prenatal dosage forms.

Provided is a method for efficiently producing ferric citrate hydrate with high purity and various specific surface areas. The method for producing modified ferric citrate hydrate includes a step of bringing a solution containing water, citric acid, and ferric citrate as a material into contact with water-soluble organic solvent.

An agent for ameliorating and/or preventing sickle cell disease, includes 5-aminolevulinic acid (ALA) or a derivative thereof or a salt thereof. The agent is useful for amelioration and/or prevention of sickle cell disease. The agent may include one or more kinds of metal-including compounds. The metal in the metal-including compound can be any of several different metals, including iron, magnesium, zinc, nickel, vanadium, copper, chromium, molybdenum, or cobalt.

An agent for ameliorating and/or preventing sickle cell disease, includes 5-aminolevulinic acid (ALA) or a derivative thereof or a salt thereof. The agent is useful for amelioration and/or prevention of sickle cell disease. The agent may include one or more kinds of metal-including compounds. The metal in the metal-including compound can be any of several different metals, including iron, magnesium, zinc, nickel, vanadium, copper, chromium, molybdenum, or cobalt.

The use of carboxylate ligand modified ferric iron hydroxide compositions for the treatment or prevention of iron deficiency associated with liver diseases is disclosed, and more particularly to the class of Iron Hydroxide Adipate Tartrate (IHAT) materials for 10 use in the treatment or prevention of iron deficiency associated with non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH).